← SynDRA
ROGARATINIB
SynDRA canonical compound SYN0038669 — structure-anchored drug synonym record
| Clinical phase | Phase 2/Phase 3 |
|---|
| Primary target(s) | FGFR1 | FGFR2 | FGFR3 | FGFR4 |
|---|
| Mechanism of action | FGFR inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- FGFR3 INHIBITOR
- Fibroblast growth factor receptor inhibitor
- FGFR1 INHIBITOR
- FGFR4 INHIBITOR
- FGFR2 INHIBITOR
- FGFR inhibitor
Cross-references
Synonyms
- BAY-1163877
- BAY1163877
- BAY 1163877
- rogaratinibum
- RefChem:179770
- Rogaratinib [INN]
- Rogaratinib?
- ROGARATINIB [WHO-DD]
- UNII-98BSN6N516
- GTPL9789
- orb1706697
- SCHEMBL15023004
- SCHEMBL29358162
- C23H26N6O3S
- BDBM194820
- EX-A1423
- THC53005
- MFCD30533278
- NSC804518
- AKOS040742570
- CS-8129
- Example 1 [WO2013087578]
- NSC-804518
- SB19772
- AC-36553
- DA-77526
- MS-28600
- HY-100019
- G15939
- T16781
- US9206184, 1
- US9206184, 2
- SCHEMBL15023316
- UNII-25AM6LVL9J
- Rogaratinib dihydrochloride
- rogaratinib dihydrochloride
Look up ROGARATINIB in the interactive SynDRA portal →